Advice
Following an abbreviated submission
ciclesonide inhaler (Alvesco®) is accepted for use within NHS Scotland at high doses (up to 640mcg daily for up to 12 weeks) to control persistent asthma in adolescents and adults (12 years and older).
The higher dose should be used in patients for whom ciclesonide is an appropriate choice of maintenance inhaled corticosteroid therapy. Alternative inhaled steroids are available at lower costs.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- ciclesonide 80mcg , 160mcg inhaler (Alvesco)
- SMC ID:
- 412/07
- Indication:
- Asthma in adolescents and adults (12 years and older)
- Pharmaceutical company
- Altana Pharma Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 November 2007